2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miyata, T. Articles by Kurokawa, K. Search for Related Content PubMed PubMed Citation Articles by Miyata, T. Articles by Kurokawa, K.

Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End Products: Biochemical Mechanisms

Toshio Miyata^*, Charles van Ypersele de Strihou, Yasuhiko Ueda^*, Kohji Ichimori^*, Reiko Inagi^*, Hiroshi Onogi^*, Naoyoshi Ishikawa^*, Masaomi Nangaku and Kiyoshi Kurokawa^*

*Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan; Service de Nephrologie, Universite Catholique de Louvain, Brussels, Belgium; and Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan.

Correspondence to: Dr. Toshio Miyata, Molecular and Cellular Nephrology, Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. Phone: +81-463-93-1936; Fax: +81-463-93-1938;

ABSTRACT. The implication of advanced glycation end products (AGE) in the pathogenesis of atherosclerosis and of diabetic and uremic complications has stimulated a search for AGE inhibitors. This study evaluates the AGE inhibitory potential of several well-tolerated hypotensive drugs. Olmesartan, an angiotensin II type 1 receptor (AIIR) antagonist, as well as temocaprilat, an angiotensin-converting enzyme (ACE) inhibitor, unlike nifedipine, a calcium blocker, inhibit in vitro the formation of two AGE, pentosidine and N-carboxymethyllysine (CML), during incubation of nonuremic diabetic, nondiabetic uremic, or diabetic uremic plasma or of BSA fortified with arabinose. This effect is shared by all tested AIIR antagonists and ACE inhibitors. On an equimolar basis, they are more efficient than aminoguanidine or pyridoxamine. Unlike the latter two compounds, they do not trap reactive carbonyl precursors for AGE, but impact on the production of reactive carbonyl precursors for AGE by chelating transition metals and inhibiting various oxidative steps, including carbon-centered and hydroxyl radicals, at both the pre- and post-Amadori steps. Their effect is paralleled by a lowered production of reactive carbonyl precursors. Finally, they do not bind pyridoxal, unlike aminoguanidine. Altogether, this study demonstrates for the first time that widely used hypotensive agents, AIIR antagonists and ACE inhibitors, significantly attenuate AGE production. This study provides a new framework for the assessment of families of AGE-lowering compounds according to their mechanisms of action. E-mail: t-miyata@is.icc.u-tokai.ac.jp

This article has been cited by other articles:

				Y. Izuhara, T. Sada, H. Yanagisawa, H. Koike, S. Ohtomo, T. Dan, S. Ito, M. Nangaku, C. van Ypersele de Strihou, and T. Miyata A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1767 - 1773. [Abstract] [Full Text] [PDF]

				H. L. Nienhuis, K. de Leeuw, J. Bijzet, A. Smit, C. G. Schalkwijk, R. Graaff, C. G. Kallenberg, and M. Bijl Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts Rheumatology, October 1, 2008; 47(10): 1554 - 1558. [Abstract] [Full Text] [PDF]

				Y. Izuhara, M. Nangaku, S. Takizawa, S. Takahashi, J. Shao, H. Oishi, H. Kobayashi, C. van Ypersele de Strihou, and T. Miyata A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models Nephrol. Dial. Transplant., February 1, 2008; 23(2): 497 - 509. [Abstract] [Full Text] [PDF]

				E. N. Lavrentyev, A. M. Estes, and K. U. Malik Mechanism of High Glucose Induced Angiotensin II Production in Rat Vascular Smooth Muscle Cells Circ. Res., August 31, 2007; 101(5): 455 - 464. [Abstract] [Full Text] [PDF]

				M. T. Coughlan, V. Thallas-Bonke, J. Pete, D. M. Long, A. Gasser, D. C. K. Tong, M. Arnstein, S. R. Thorpe, M. E. Cooper, and J. M. Forbes Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy? Endocrinology, February 1, 2007; 148(2): 886 - 895. [Abstract] [Full Text] [PDF]

				A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury Circulation, August 8, 2006; 114(6): 597 - 605. [Abstract] [Full Text] [PDF]

				A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]

				T. Miyata and C. van Ypersele de Strihou Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering Nephrol. Dial. Transplant., April 1, 2006; 21(4): 846 - 849. [Full Text] [PDF]

				M. Nangaku, Y. Izuhara, N. Usuda, R. Inagi, T. Shibata, S. Sugiyama, K. Kurokawa, C. van Ypersele de Strihou, and T. Miyata In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2661 - 2669. [Abstract] [Full Text] [PDF]

				Y. Kikuchi, T. Imakiire, T. Hyodo, T. Kushiyama, K. Higashi, N. Hyodo, S. Suzuki, and S. Miura Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2690 - 2696. [Abstract] [Full Text] [PDF]

				Y. Izuhara, M. Nangaku, R. Inagi, N. Tominaga, T. Aizawa, K. Kurokawa, C. van Ypersele de Strihou, and T. Miyata Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3631 - 3641. [Abstract] [Full Text] [PDF]

				F. Waanders, W. L. Greven, J. W. Baynes, S. R. Thorpe, A. B. Kramer, R. Nagai, N. Sakata, H. van Goor, and G. Navis Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2060 - 2070. [Abstract] [Full Text] [PDF]

				J. M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659. [Abstract] [Full Text] [PDF]

				Y. Kikuchi, T. Imakiire, M. Yamada, T. Saigusa, T. Hyodo, N. Hyodo, S. Suzuki, and S. Miura Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1573 - 1581. [Abstract] [Full Text] [PDF]

				J. M. Forbes, S. R. Thorpe, V. Thallas-Bonke, J. Pete, M. C. Thomas, E. R. Deemer, S. Bassal, A. El-Osta, D. M. Long, S. Panagiotopoulos, et al. Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2363 - 2372. [Abstract] [Full Text] [PDF]

				R. Harris Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy: It's All the RAGE J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2251 - 2253. [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				Q. Fan, J. Liao, M. Kobayashi, M. Yamashita, L. Gu, T. Gohda, Y. Suzuki, L. N. Wang, S. Horikoshi, and Y. Tomino Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3012 - 3020. [Abstract] [Full Text] [PDF]

				J. M. Forbes, L. T. L. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, M. C. Thomas, W. C. Burns, E. K. Deemer, S. R. Thorpe, et al. Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis Diabetes, July 1, 2004; 53(7): 1813 - 1823. [Abstract] [Full Text] [PDF]

				S. M. Culbertson, E. I. Vassilenko, L. D. Morrison, and Keith. U. Ingold Paradoxical Impact of Antioxidants on Post-Amadori Glycoxidation: COUNTERINTUITIVE INCREASE IN THE YIELDS OF PENTOSIDINE AND N{epsilon}-CARBOXYMETHYLLYSINE USING A NOVEL MULTIFUNCTIONAL PYRIDOXAMINE DERIVATIVE J. Biol. Chem., October 3, 2003; 278(40): 38384 - 38394. [Abstract] [Full Text] [PDF]

				J. M. Forbes, M. E. Cooper, M. D. Oldfield, and M. C. Thomas Role of Advanced Glycation End Products in Diabetic Nephropathy J. Am. Soc. Nephrol., August 1, 2003; 14(90003): S254 - 258. [Abstract] [Full Text] [PDF]

				M. Nangaku, T. Miyata, T. Sada, M. Mizuno, R. Inagi, Y. Ueda, N. Ishikawa, H. Yuzawa, H. Koike, C. van Ypersele de Strihou, et al. Anti-Hypertensive Agents Inhibit In Vivo the Formation of Advanced Glycation End Products and Improve Renal Damage in a Type 2 Diabetic Nephropathy Rat Model J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1212 - 1222. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673